title: A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease.
abstract: Earlier studies in diabetic animal models or ex vivo from diabetics suggest a deficiency in prostacyclin (PGI2) production and an increase in an alternate arachidonic acid metabolite, 12-hydroxyeicosatetraenoic acid (12-HETE), which stimulates angiogenesis, mitogenesis, and inhibits renin secretion. We studied the urinary excretion rate of 6-keto-PGF1 alpha (a stable metabolite of PGI2) and 12-HETE in controls and 42 noninsulin-dependent diabetes mellitus (NIDDM) patients with normal renal function and those with micro- or macroalbuminuria/hyporeninemic hypoaldosteronism (HH). The 2 eicosanoids were measured in urine using previously described high pressure liquid chromatography and RIA methods. Normal subjects and patients with NIDDM and microalbuminuria were infused with low dose calcium infusions that stimulate prostacyclin production in normal subjects. The PGI2 excretion rate of NIDDM patients with normal renal function was not different from that of controls (143 +/- 17 vs. 118 +/- 34 ng/g creatinine), but was reduced in those with microalbuminuria (75 +/- 10) and in macroalbuminuria patients (48 +/- 7; P < 0.01). In contrast, 12-HETE was increased in diabetics with normal renal function as well as in those with micro- or macroalbuminuria patients (69 +/- 18 vs. 250 +/- 62 vs. 226 +/- 60 and 404 +/- 131 ng/g creatinine; P < 0.01). Calcium did not stimulate PGI2, but increased 12-HETE in diabetics with microalbuminuria in contrast to levels in normal subjects. HH patients excreted less PGI2 (as previously reported), but had increased 12-HETE. HETE/PGI2 ratios further demonstrated these changes in the various groups. In a nondiabetic hypertensive microalbuminuria group, 12-HETE excretion was normal (73 +/- 28 ng/g creatinine). We conclude that the lipoxygenase product 12-HETE is increased early in the diabetic process, whereas PGI2 production is progressively impaired in NIDDM. These changes may play a role in the vascular disease of diabetes and partially explain the HH syndrome.
authors.affiliation: Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA.
authors.forename: I
authors.initials: I
authors.lastname: Antonipillai
authors.forename: J
authors.initials: J
authors.lastname: Nadler
authors.forename: E J
authors.initials: EJ
authors.lastname: Vu
authors.forename: S
authors.initials: S
authors.lastname: Bughi
authors.forename: R
authors.initials: R
authors.lastname: Natarajan
authors.forename: R
authors.initials: R
authors.lastname: Horton
mesh_terms: D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000652:urine; D001092:Arachidonate 12-Lipoxygenase / Q000378:metabolism*; D002118:Calcium / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000652:urine*; D003928:Diabetic Nephropathies / Q000652:urine*; D011464:Epoprostenol / Q000652:urine; D005260:Female; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000652:urine*; D006994:Hypoaldosteronism / Q000652:urine; D008297:Male; D008875:Middle Aged; D012083:Renin / Q000097:blood
chemical_list: D006893:Hydroxyeicosatetraenoic Acids; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D011464:Epoprostenol; D001092:Arachidonate 12-Lipoxygenase; D012083:Renin; D002118:Calcium